• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Novartis Sues Noven Over Generic Dementia Patch

Quote

Anonymous

Guest
This makes things scary for anyone being retained...

Novartis Sues Noven Over Generic Dementia Patch

Share us on:TwitterFacebookLinkedInBy Kira Lerner 0 Comments

Law360, New York (January 31, 2014, 3:27 PM ET) -- Novartis AG hit Hisamitsu Pharmaceutical Co. Inc. and subsidiary Noven Pharmaceuticals Inc. with a suit in Delaware federal court Thursday, claiming Noven’s proposed generic version of the Exelon patch, used to treat dementia, infringes patents covering the drug.

According to the Swiss pharmaceutical giant, Japan-based Hisamitsu and two Noven units’ planned 13.3 milligram drug containing the active ingredient rivastigmine and used to treat dementia infringes U.S. Patent Nos. 6,316,023 and 6,335,031, patents jointly owned by Novartis and German transdermal patch specialist LTS Lohmann Therapie-Systeme AG....
 




Anonymous said:
This makes things scary for anyone being retained...

Novartis Sues Noven Over Generic Dementia Patch

Share us on:TwitterFacebookLinkedInBy Kira Lerner 0 Comments

Law360, New York (January 31, 2014, 3:27 PM ET) -- Novartis AG hit Hisamitsu Pharmaceutical Co. Inc. and subsidiary Noven Pharmaceuticals Inc. with a suit in Delaware federal court Thursday, claiming Noven’s proposed generic version of the Exelon patch, used to treat dementia, infringes patents covering the drug.

According to the Swiss pharmaceutical giant, Japan-based Hisamitsu and two Noven units’ planned 13.3 milligram drug containing the active ingredient rivastigmine and used to treat dementia infringes U.S. Patent Nos. 6,316,023 and 6,335,031, patents jointly owned by Novartis and German transdermal patch specialist LTS Lohmann Therapie-Systeme AG....
Click to expand...

Wow possibly no drugs to sell...
 




Novartis knew about this a year ago. Interesting that Nikos covered over the issue in his e-mail and again isn't it interesting that Lisa Deschamps was removed from Exelon to Xolair at the end of the summer prior to all of this coming to aa head!
 












Anonymous said:
actually a very strategic move, as any litigation prevents the generic drug to be sold; BUT... at some point in time Novartis will lose exclusivity and then what ?
Click to expand...

Wrong!!!!!!!!!!! Generics can still launch, but at risk while litigation is proceeding. Apotex did this with Plavix and eventually lost their patent challenge.
 








Anonymous said:
actually a very strategic move, as any litigation prevents the generic drug to be sold; BUT... at some point in time Novartis will lose exclusivity and then what ?
Click to expand...

Its standard procedure, slow them down through litigation, ramp the price, milch the cow, and when you finally see a volume generic product in market your rep job is over. EP price will hike as soon as the first generic patch is on a patient. Then those that can afford the premium and have brand loyalty to the EP will stay and pay, but you don't need reps at that stage as you carry no added value. so its redeploy or pink slip time and a message from Nikos thanking you for all the great work you did whist he sends you a UPS box to ship your iPad back.
 




Top Bottom
Back
Quote